<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20140415017288N9</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-02-03</date_registration>
      <primary_sponsor>Islamic Azad University</primary_sponsor>
      <public_title>Effect of Exercise and Salvia officinalis on Postmenopausal Women</public_title>
      <acronym></acronym>
      <scientific_title>Preventive effects of Exercise Training and Salvia officinalis on Inflammation and Insulin Resistance in Postmenopausal Women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-01-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>32</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67473</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: In this research, subjects are selected by Simple randomization by the random allocation rule. After determining the sample size (32 people), numbers 1 to 4 are written on 32 small separate papers (8 sheets of paper for each number) and placed in a container. Number 1 is for the Placebo Control group (C), number 2 is for the Aerobic Training Group (AT), number 3 is for the Salvia Officinalis group (So) and number 4 is for the Training-Salvia Officinalis (ATSo). Then each sheet of paper is randomly taken out by the subjects and placed in the intervention or placebo groups, respectively, Blinding description: All the study groups received the supplement in sealed packages that were coded. Coding is done by the researcher and the subjects do not know about it. The Salvia officinalis (So) and Training-Salvia Officinalis (ATSo) receive three 100 mg tablets of So for eight weeks. Placebo Control (C), and Aerobic Training (AT) groups receive a placebo in the same pharmacological presentation. Starch is used as a placebo.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Postmenopausal Women. Condition 2: Insulin resistance.</hc_freetext>
      <i_freetext>Intervention 1: Control group: This group received three 100 mg starch tablets as a placebo during the 8-week intervention period. Intervention 2: Intervention group 1: Training group (in this group for eight-week, three session/weeks, the training start with 10 min warming and then 25 to 45 min training with 40% Maximum heart rate reserve, which in the final weeks reaches 80% of the Maximum heart rate reserve. Also, this group received three 100 mg starch tablets as a placebo during the 8-week intervention period). Intervention 3: Intervention group 2: Intervention group: Salvia officinalis supplement group (this group receives three tablets of 100 mg of So orally daily). Intervention 4: Intervention group 3: Training+ Salvia officinalis supplementation group (In this group the Simultaneous intervention, training, and Salvia officinalis supplementation, will treat with the same protocol describes in the previous part).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Information on the main outcomes will be shared.

When:
Since 2023

To whom:
All researchers

Conditions:
If people email the person responsible for the plan, they can get the desired documents in the form of a file.

Where to obtain:
People can apply for documents through email.

How to obtain:
Maximum one week

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ahmad Abdi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Old Amol-Babol road, Kamdereh village- Ayatollah Amoli Branch, Islamic Azad University</address>
        <city>Amol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>678</zip>
        <telephone>+98 11 4321 7124</telephone>
        <email>a.abdi@iauamol.ac.ir</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Alireza Barari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Old Amol-Babol road, Kamdereh village- Ayatollah Amoli Branch, Islamic Azad University</address>
        <city>Amol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>678</zip>
        <telephone>+98 11 4321 7126</telephone>
        <email>alireza54.barari@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>being menopausal
Age range 50-65 years
Inactive lifestyle (exercise less than 1 hour per week)
Not taking medicine in the last 6 months.
Being willing to participate in the study.</inclusion_criteria>
      <agemin>50 years</agemin>
      <agemax>65 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Supplement use.
Diagnosis of other diseases during the implementation of the protocol.
Not taking Salvia officinalis.
Use of estrogen and other androgens and steroids that affect estrogen receptors.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Z79.890</hc_code>
      <hc_code>R73.02</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Postmenopausal</hc_keyword>
      <hc_keyword>Impaired glucose tolerance (oral)</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Placebo</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: This group received three 100 mg starch tablets as a placebo during the 8-week intervention period.</i_keyword>
      <i_keyword>Intervention group 1: Training group (in this group for eight-week, three session/weeks, the training start with 10 min warming and then 25 to 45 min training with 40% Maximum heart rate reserve, which in the final weeks reaches 80% of the Maximum heart rate reserve. Also, this group received three 100 mg starch tablets as a placebo during the 8-week intervention period).</i_keyword>
      <i_keyword>Intervention group 2: Intervention group: Salvia officinalis supplement group (this group receives three tablets of 100 mg of So orally daily).</i_keyword>
      <i_keyword>Intervention group 3: Training+ Salvia officinalis supplementation group (In this group the Simultaneous intervention, training, and Salvia officinalis supplementation, will treat with the same protocol describes in the previous part).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Tumor Necrosis Factor Alpha. Timepoint: Before and after the protocol. Method of measurement: Biochemical and laboratory methods (by ELISA method).</prim_outcome>
      <prim_outcome>Interleukin-10. Timepoint: Before and after the protocol. Method of measurement: Biochemical and laboratory methods (by ELISA method).</prim_outcome>
      <prim_outcome>Interleukin-12. Timepoint: Before and after the protocol. Method of measurement: Biochemical and laboratory methods (by ELISA method).</prim_outcome>
      <prim_outcome>Fasting blood glucose. Timepoint: Before and after the protocol. Method of measurement: Biochemical methods.</prim_outcome>
      <prim_outcome>Fasting blood insulin. Timepoint: Before and after the protocol. Method of measurement: Biochemical and laboratory methods (by ELISA method).</prim_outcome>
      <prim_outcome>Insulin resistance index (HOMA-IR). Timepoint: Before and after the protocol. Method of measurement: formulas.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Islamic Azad University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-11-26</approval_date>
        <contact_name>Ethics Committee of Islamic Azad University - Marvdasht Branch</contact_name>
        <contact_address>3 km of Marvdasht-Persepolis Boulevard, Islamic Azad University, Marvdasht Branch Marvdasht Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
